Abeona Therapeutics (ABEO) Stock Overview
A clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
ABEO Community Fair Values
Create NarrativeSee what 23 others think this stock is worth. Follow their fair value or set your own to get alerts.
Abeona Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.17 |
| 52 Week High | US$7.54 |
| 52 Week Low | US$3.93 |
| Beta | 1.12 |
| 1 Month Change | -22.20% |
| 3 Month Change | -36.43% |
| 1 Year Change | -31.70% |
| 3 Year Change | 3.22% |
| 5 Year Change | -86.97% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Abeona Therapeutics: ZEVASKYN Data Key In Gauging Momentum - Why I Hold
Nov 10Health Check: How Prudently Does Abeona Therapeutics (NASDAQ:ABEO) Use Debt?
Jan 15
Is Abeona Therapeutics (NASDAQ:ABEO) Using Too Much Debt?
Sep 23We're Not Very Worried About Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Rate
May 01We're Not Very Worried About Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Rate
Jan 04Here's Why We're Watching Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn Situation
Aug 16Can Abeona Therapeutics (NASDAQ:ABEO) Afford To Invest In Growth?
Mar 31Abeona: Pivotal Data Readout EB-101 Before Year End Could Boost Shareholder Value
Oct 19Abeona Therapeutics stock continues recent strong run, shares rise ~10%
Oct 04Abeona Therapeutics GAAP EPS of -$2.08, revenue of $1M
Aug 11Abeona therapeutics regains compliance with Nasdaq minimum bid price requirement
Jul 20Abeona crashes 21% as reverse stock split takes effect
Jul 05Here's Why Abeona Therapeutics (NASDAQ:ABEO) Must Use Its Cash Wisely
Mar 02Here's Why Abeona Therapeutics (NASDAQ:ABEO) Can Manage Its Debt Despite Losing Money
Aug 17Despite Lacking Profits Abeona Therapeutics (NASDAQ:ABEO) Seems To Be On Top Of Its Debt
Apr 28Independent Director Paul Mann Just Sold A Bunch Of Shares In Abeona Therapeutics Inc. (NASDAQ:ABEO)
Feb 21How Much Did Abeona Therapeutics'(NASDAQ:ABEO) Shareholders Earn From Share Price Movements Over The Last Three Years?
Jan 19What Kind Of Investors Own Most Of Abeona Therapeutics Inc. (NASDAQ:ABEO)?
Dec 15
Shareholder Returns
| ABEO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -8.6% | 5.4% | 0.9% |
| 1Y | -31.7% | 7.7% | 13.8% |
Return vs Industry: ABEO underperformed the US Biotechs industry which returned 1.4% over the past year.
Return vs Market: ABEO underperformed the US Market which returned 12.9% over the past year.
Price Volatility
| ABEO volatility | |
|---|---|
| ABEO Average Weekly Movement | 6.9% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: ABEO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ABEO's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1974 | 136 | Vish Seshadri | www.abeonatherapeutics.com |
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is pz-cel, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy.
Abeona Therapeutics Inc. Fundamentals Summary
| ABEO fundamental statistics | |
|---|---|
| Market cap | US$216.91m |
| Earnings (TTM) | US$57.24m |
| Revenue (TTM) | US$400.00k |
Is ABEO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABEO income statement (TTM) | |
|---|---|
| Revenue | US$400.00k |
| Cost of Revenue | US$33.92m |
| Gross Profit | -US$33.52m |
| Other Expenses | -US$90.76m |
| Earnings | US$57.24m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Nov 12, 2025
| Earnings per share (EPS) | 1.12 |
| Gross Margin | -8,379.75% |
| Net Profit Margin | 14,310.50% |
| Debt/Equity Ratio | 12.0% |
How did ABEO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/11 07:00 |
| End of Day Share Price | 2025/11/11 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Abeona Therapeutics Inc. is covered by 21 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| George Zavoico | B. Riley Securities, Inc. |
| Kristen Kluska | Cantor Fitzgerald & Co. |